Exploring the Current Practices,Costs and Benefits of FAIR Implementation in Pharmaceutical Research and Development:A Qualitative Interview Study

作     者：Ebtisam Alharbi Rigina Skeva Nick Juty Caroline Jay Carole Goble 

作者机构：School of Computer ScienceUniversity of ManchesterManchesterManchester M139PLUK College of Computer and Information SystemsUmm Al-Qura UniversityMeccaMakkah 21421Saudi Arabia 

出 版 物：《Data Intelligence》 (数据智能（英文）)

年 卷 期：2021年第3卷第4期

页      面：507-527页

核心收录：

学科分类：0810[工学-信息与通信工程] 1205[管理学-图书情报与档案管理] 12[管理学] 1007[医学-药学(可授医学、理学学位)] 1201[管理学-管理科学与工程(可授管理学、工学学位)] 0811[工学-控制科学与工程] 0812[工学-计算机科学与技术（可授工学、理学学位）] 10[医学] 

基　　金：the FAIRplus project(IMI2 Joint Undertaking under grant agreement No.802750) The EPSRC supported C.Jay in this work under EP/S021779/1 E.Alharbi’s scholarship is sponsored by Umm Al-Qura University,the Kingdom of Saudi Arabia(No.1057493924) 

主　　题：FAIR FAIRification Retrospective FAIRification Pharmaceutical R&D Cost-benefit Decision-making process 

摘      要：The findable,accessible,interoperable,reusable(FAIR)principles for scientific data management and stewardship aim to facilitate data reuse at scale by both humans and *** and development(R&D)in the pharmaceutical industry is becoming increasingly data driven,but managing its data assets according to FAIR principles remains costly and *** date,little scientific evidence exists about how FAIR is currently implemented in practice,what its associated costs and benefits are,and how decisions are made about the retrospective FAIRification of data sets in pharmaceutical R&*** paper reports the results of semi-structured interviews with 14 pharmaceutical professionals who participate in various stages of drug R&D in seven pharmaceutical *** thematic analysis identified three primary themes of the benefits and costs of FAIRification,and the elements that influence the decision-making process for FAIRifying legacy data *** collectively acknowledged the potential contribution of FAIRification to data reusability in diverse research domains and the subsequent potential for *** costs,however,were still considered a barrier by participants,with the need for considerable expenditure in terms of resources,and cultural *** decisions were made about FAIRification was influenced by legal and ethical considerations,management commitment,and data *** findings have significant implications for those in the pharmaceutical R&D industry who are engaged in driving FAIR implementation,and for external parties who seek to better understand existing practices and challenges.